HMT venta

Found within any biological sample of living organisms, metabolomes are sets of small-molecule metabolites, produced as a result of physiological processes. Metabolomes can offer unparalleled insights into the interactions between different
chemical components and their role in various physiological functions. Apart from traditional diagnosis, metabolic profiling of
biological samples in drug discovery and development help healthcare companies and researchers understand the mechanism of action, surrogate markers, and toxicity of potential drug candidates. Eliminating the potential toxic drug candidates before a clinical trial begins assists customers in saving billions of dollars. The critical application of this field of study has also seen a surge in metabolomics platform providers. Currently, the European market is on the verge of this tectonic shift that is redefining the traditional biomarker discovery and drug development processes through collaboration between pharmaceutical, academic, healthcare companies, and metabolomic platform providers.

Human Metabolome Technologies Inc. (HMT) President and CEO Ryuji Kanno announced today that the joint patent application for Phosphoethanolamine as a biomarker of MDD was granted in the EU. This was conducted in collaboration with Noriyuki Kawamura, Director of the Medical Corporation Association Gyo-ki kai Kawamura General Clinic (Minato-ku, Tokyo), and has officially been accepted and granted in the European market. This is in addition to the registration of the patents in Japan, USA, and China. The corresponding patent identification numbers are 5372213 in Japan), US8951739 in the USA and ZL201080046087.6 in China). The EU patent grant will not have any impact on
business performance

Newsletters 2017

Newsletters 2019

Archived Press

Newsletters 2016

Newsletters 2018

Newsletters 2015

Newsletters 2015

HMT Featured in Pharma Tech Outlook

HMT Obtains EU Patent for Diagnostic Biomarker for MDD

Purines and Pyrimidines

Sign Up for Our Newsletter